Surveilling and Tracking COVID-19 Patients Using a Portable Quantum Dot Smartphone Device.
Yuwei ZhangAyden MalekjahaniBuddhisha N UdugamaPranav KadhiresanHongmin ChenMatthew OsborneMax FranzMike KuceraSimon PlenderleithLily YipGary D BaderVanessa TranJonathan B GubbayAllison McGeerSamira MubarekaWarren W C ChanPublished in: Nano letters (2021)
The ability to rapidly diagnose, track, and disseminate information for SARS-CoV-2 is critical to minimize its spread. Here, we engineered a portable smartphone-based quantum barcode serological assay device for real-time surveillance of patients infected with SARS-CoV-2. Our device achieved a clinical sensitivity of 90% and specificity of 100% for SARS-CoV-2, as compared to 34% and 100%, respectively, for lateral flow assays in a head-to-head comparison. The lateral flow assay misdiagnosed ∼2 out of 3 SARS-CoV-2 positive patients. Our quantum dot barcode device has ∼3 times greater clinical sensitivity because it is ∼140 times more analytically sensitive than lateral flow assays. Our device can diagnose SARS-CoV-2 at different sampling dates and infectious severity. We developed a databasing app to provide instantaneous results to inform patients, physicians, and public health agencies. This assay and device enable real-time surveillance of SARS-CoV-2 seroprevalence and potential immunity.
Keyphrases
- sars cov
- public health
- end stage renal disease
- ejection fraction
- respiratory syndrome coronavirus
- chronic kidney disease
- high throughput
- prognostic factors
- peritoneal dialysis
- risk assessment
- healthcare
- patient reported outcomes
- social media
- molecular dynamics
- optical coherence tomography
- patient reported
- energy transfer